GPCR Structure Therapeutics Inc. American Depositary Shares

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has received a "Moderate Buy" consensus recommendation from fourteen brokerages, with an average 12-month price target of $99.11. The company reported a ($0.37) EPS last quarter, missing estimates, and analysts forecast (-0.82) EPS for the current year. Institutional investors hold approximately 91.78% of the stock.

Structure Therapeutics (GPCR) has seen its stock price surge despite having no revenue and ongoing losses, leading to a 5x price-to-book multiple. While this valuation is high compared to the broader US pharmaceuticals industry, it reflects investor optimism regarding its obesity and fibrosis programs. However, setbacks in clinical trials could quickly diminish this premium.

Structure Therapeutics (GPCR) is concluding 2025 as a key player in the oral weight-loss drug market, driven by positive Phase 2 clinical data for aleniglipron (GSBR-1290), a substantial $747.5 million capital raise, and the initiation of a Phase 1 study for its oral amylin program (ACCG-2671). The company's stock has seen increased analyst price targets, but also faces heightened competition, especially following the FDA approval of Novo Nordisk's Wegovy pill on December 23, 2025. Investors are now closely watching upcoming regulatory alignments for Phase 3 and Phase 1 readouts for ACCG-2671 as key catalysts for 2026.

H.C. Wainwright has raised its price target for Structure Therapeutics (NASDAQ: GPCR) to $90 from $60, maintaining a Buy rating after reviewing positive Phase 2 data for the company's oral GLP-1 therapy. The firm projects "injectable-like" efficacy without a plateau in Phase 3 trials and views the current valuation as a "massive arbitrage opportunity" given the strong M&A potential in oral GLP-1 therapies. This upgrade follows other positive analyst revisions and recent company developments, including a successful public offering and the initiation of a new clinical study.

This article provides comprehensive stock information for Structure Therapeutics Inc. (GPCR), including its current price, financial metrics, analyst ratings, and a chronological list of recent news and press releases. The company is a clinical-stage biopharmaceutical firm focused on developing oral therapeutics for chronic diseases, particularly in the obesity and diabetes space, with several drug candidates in its pipeline.

Structure Therapeutics (NASDAQ:GPCR) shares gapped up significantly before trading on Friday, opening at $66.03 after closing at $62.45. The biopharmaceutical company, which is developing an oral GLP-1 agonist, saw its stock trading around $66.68, marking an intraday rise of approximately 10.2%. This surge followed several bullish analyst target raises, contributing to a "Moderate Buy" consensus rating and an average price target of $99.11.